Compare Efficacy and Safety of Repeated Courses of Rituximab to That of Maintenance Mycophenolate Mofetil Following Single Course of Rituximab Among Children With Steroid Dependent Nephrotic Syndrome

Inclusion Criteria * Children between 3 and 16 years with SDNS. * Minimal Change disease/ FSGS/MesPGN as per Kidney Biopsy report. * Estimated glomerular filtration rate (eGFR) \>80 ml/min per 1.73 m2 at study entry. * Remission at study entry (Urine albumin nil or trace (or proteinuria \<4 mg/m2/h) for 3 consecutive early morning specimens). * Not received any steroid sparing agent previously. * Parents willing to give informed written and audiovisual consent. * Ability to swallow tablet. Exclusion Criteria * Known etiology (e.g., lupus erythematosus, IgA nephropathy, amyloidosis, malignancy, other secondary forms of NS). * Patients with severe leukopenia (leukocytes \<3.0× 1000 cells/mm3), severe anemia (haemoglobin \<8.9 g/dl), thrombocytopenia (platelet \<100.0 × 1000 cells/mm3) or deranged liver function tests (AST or ALT to \>50 IU/L ) at enrolment. * Known active chronic infection (tuberculosis, HIV, hepatitis B or C). * Live vaccination within one month prior to screening.